tauotetussa
Tauotetussa is a muscle relaxant medication used to treat muscle spasticity. It is a member of the GABA-transaminase inhibiting compound class, which works by inhibiting the activity of GABA-transaminase, an enzyme involved in the breakdown of the neurotransmitter GABA. By blocking this enzyme, tauotetussa increases GABA levels in the central nervous system, leading to its muscle relaxant effects.
Tauotetussa was first approved for use in Russia in 2006, under the brand name "Tauotetussa". It has
Common side effects of tauotetussa include dizziness, fatigue, and muscle weakness. More serious side effects, such
Tauotetussa is thought to be as effective as traditional muscle relaxants, such as baclofen and tizanidine,